Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Triple-Drug attack shows promise against tough prostate cancer

NCT ID NCT04126070

First seen Jan 23, 2026 · Last updated May 22, 2026 · Updated 14 times

Summary

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy and hormone therapy can better control advanced prostate cancer that has spread. It includes 60 men with a specific genetic feature or inflamed tumors. The goal is to see if this combination lowers PSA levels more effectively.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

  • H. Lee Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • The Johns Hopkins University School of Medicine

    Baltimore, Maryland, 21218, United States

  • University of California, San Diego

    La Jolla, California, 92093, United States

  • University of Wisconsin

    Madison, Wisconsin, 53706, United States

Conditions

Explore the condition pages connected to this study.